Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
45
IMCC Quote, Financials, Valuation and Earnings
Last price:
$1.52
Seasonality move
:
-16.2%
Day range:
$1.41 - $1.59
52-week range:
$0.93 - $7.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.14x
P/B ratio:
3.17x
Volume:
49.8K
Avg. volume:
273K
1-year change:
-33.03%
Market cap:
$9M
Revenue:
$39.4M
EPS (TTM):
-$0.79
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IMCC
IM Cannabis Corp.
|
$10.3M | -- | 31.7% | -- | -- |
|
INMD
InMode Ltd.
|
$90.9M | $0.35 | 6.94% | -63.36% | $16.60 |
|
IRME
IR-Med, Inc.
|
-- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-- | -$6.08 | -- | -206.85% | $399.00 |
|
PLUR
Pluri, Inc.
|
$638K | -$0.74 | 316.67% | -79.86% | $12.00 |
|
RAPH
Raphael Pharmaceutical, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IMCC
IM Cannabis Corp.
|
$1.48 | -- | $9M | -- | $0.00 | 0% | 0.14x |
|
INMD
InMode Ltd.
|
$14.47 | $16.60 | $914.6M | 6.69x | $0.00 | 0% | 2.68x |
|
IRME
IR-Med, Inc.
|
$0.04 | -- | $3.1M | -- | $0.00 | 0% | -- |
|
PHGE
BiomX, Inc.
|
$2.00 | $399.00 | $3.1M | -- | $0.00 | 0% | -- |
|
PLUR
Pluri, Inc.
|
$3.21 | $12.00 | $29.7M | -- | $0.00 | 0% | 17.55x |
|
RAPH
Raphael Pharmaceutical, Inc.
|
$1.40 | -- | $27.5M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IMCC
IM Cannabis Corp.
|
81.59% | 10.871 | 105.66% | 0.35x |
|
INMD
InMode Ltd.
|
0.85% | 1.041 | 0.59% | 8.35x |
|
IRME
IR-Med, Inc.
|
-66.67% | 8.293 | 5.39% | 0.12x |
|
PHGE
BiomX, Inc.
|
38.57% | 0.072 | 20.14% | 1.51x |
|
PLUR
Pluri, Inc.
|
149.64% | 0.573 | 81% | 0.49x |
|
RAPH
Raphael Pharmaceutical, Inc.
|
-3.35% | 7.252 | 0.52% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IMCC
IM Cannabis Corp.
|
$2M | -$3M | -25.37% | -135.96% | -29.98% | -$3M |
|
INMD
InMode Ltd.
|
$72.3M | $20.9M | 22.18% | 22.38% | 22.43% | $27M |
|
IRME
IR-Med, Inc.
|
-$4K | -$286K | -- | -- | -- | -$71K |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
|
PLUR
Pluri, Inc.
|
-$15K | -$6.4M | -77.49% | -5662.45% | -2009.49% | -$5.5M |
|
RAPH
Raphael Pharmaceutical, Inc.
|
-- | -$251K | -- | -- | -- | -$17K |
IM Cannabis Corp. vs. Competitors
-
Which has Higher Returns IMCC or INMD?
InMode Ltd. has a net margin of -27.9% compared to IM Cannabis Corp.'s net margin of 23.47%. IM Cannabis Corp.'s return on equity of -135.96% beat InMode Ltd.'s return on equity of 22.38%.
Company Gross Margin Earnings Per Share Invested Capital IMCCIM Cannabis Corp.19.72% -$0.55 $15.7M INMDInMode Ltd.77.61% $0.34 $659M -
What do Analysts Say About IMCC or INMD?
IM Cannabis Corp. has a consensus price target of --, signalling upside risk potential of 304.95%. On the other hand InMode Ltd. has an analysts' consensus of $16.60 which suggests that it could grow by 14.72%. Given that IM Cannabis Corp. has higher upside potential than InMode Ltd., analysts believe IM Cannabis Corp. is more attractive than InMode Ltd..
Company Buy Ratings Hold Ratings Sell Ratings IMCCIM Cannabis Corp.0 0 0 INMDInMode Ltd.0 6 0 -
Is IMCC or INMD More Risky?
IM Cannabis Corp. has a beta of 2.180, which suggesting that the stock is 117.961% more volatile than S&P 500. In comparison InMode Ltd. has a beta of 2.144, suggesting its more volatile than the S&P 500 by 114.37%.
-
Which is a Better Dividend Stock IMCC or INMD?
IM Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InMode Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IM Cannabis Corp. pays -- of its earnings as a dividend. InMode Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMCC or INMD?
IM Cannabis Corp. quarterly revenues are $10.1M, which are smaller than InMode Ltd. quarterly revenues of $93.2M. IM Cannabis Corp.'s net income of -$2.8M is lower than InMode Ltd.'s net income of $21.9M. Notably, IM Cannabis Corp.'s price-to-earnings ratio is -- while InMode Ltd.'s PE ratio is 6.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IM Cannabis Corp. is 0.14x versus 2.68x for InMode Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMCCIM Cannabis Corp.0.14x -- $10.1M -$2.8M INMDInMode Ltd.2.68x 6.69x $93.2M $21.9M
-
Which has Higher Returns IMCC or IRME?
IR-Med, Inc. has a net margin of -27.9% compared to IM Cannabis Corp.'s net margin of --. IM Cannabis Corp.'s return on equity of -135.96% beat IR-Med, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IMCCIM Cannabis Corp.19.72% -$0.55 $15.7M IRMEIR-Med, Inc.-- -$0.01 -$375K -
What do Analysts Say About IMCC or IRME?
IM Cannabis Corp. has a consensus price target of --, signalling upside risk potential of 304.95%. On the other hand IR-Med, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that IM Cannabis Corp. has higher upside potential than IR-Med, Inc., analysts believe IM Cannabis Corp. is more attractive than IR-Med, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IMCCIM Cannabis Corp.0 0 0 IRMEIR-Med, Inc.0 0 0 -
Is IMCC or IRME More Risky?
IM Cannabis Corp. has a beta of 2.180, which suggesting that the stock is 117.961% more volatile than S&P 500. In comparison IR-Med, Inc. has a beta of 2.696, suggesting its more volatile than the S&P 500 by 169.614%.
-
Which is a Better Dividend Stock IMCC or IRME?
IM Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IR-Med, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IM Cannabis Corp. pays -- of its earnings as a dividend. IR-Med, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMCC or IRME?
IM Cannabis Corp. quarterly revenues are $10.1M, which are larger than IR-Med, Inc. quarterly revenues of --. IM Cannabis Corp.'s net income of -$2.8M is lower than IR-Med, Inc.'s net income of -$701K. Notably, IM Cannabis Corp.'s price-to-earnings ratio is -- while IR-Med, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IM Cannabis Corp. is 0.14x versus -- for IR-Med, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMCCIM Cannabis Corp.0.14x -- $10.1M -$2.8M IRMEIR-Med, Inc.-- -- -- -$701K
-
Which has Higher Returns IMCC or PHGE?
BiomX, Inc. has a net margin of -27.9% compared to IM Cannabis Corp.'s net margin of --. IM Cannabis Corp.'s return on equity of -135.96% beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital IMCCIM Cannabis Corp.19.72% -$0.55 $15.7M PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About IMCC or PHGE?
IM Cannabis Corp. has a consensus price target of --, signalling upside risk potential of 304.95%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 8150%. Given that BiomX, Inc. has higher upside potential than IM Cannabis Corp., analysts believe BiomX, Inc. is more attractive than IM Cannabis Corp..
Company Buy Ratings Hold Ratings Sell Ratings IMCCIM Cannabis Corp.0 0 0 PHGEBiomX, Inc.1 0 0 -
Is IMCC or PHGE More Risky?
IM Cannabis Corp. has a beta of 2.180, which suggesting that the stock is 117.961% more volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.
-
Which is a Better Dividend Stock IMCC or PHGE?
IM Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IM Cannabis Corp. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMCC or PHGE?
IM Cannabis Corp. quarterly revenues are $10.1M, which are larger than BiomX, Inc. quarterly revenues of --. IM Cannabis Corp.'s net income of -$2.8M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, IM Cannabis Corp.'s price-to-earnings ratio is -- while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IM Cannabis Corp. is 0.14x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMCCIM Cannabis Corp.0.14x -- $10.1M -$2.8M PHGEBiomX, Inc.-- -- -- -$9.2M
-
Which has Higher Returns IMCC or PLUR?
Pluri, Inc. has a net margin of -27.9% compared to IM Cannabis Corp.'s net margin of -1940.51%. IM Cannabis Corp.'s return on equity of -135.96% beat Pluri, Inc.'s return on equity of -5662.45%.
Company Gross Margin Earnings Per Share Invested Capital IMCCIM Cannabis Corp.19.72% -$0.55 $15.7M PLURPluri, Inc.-4.75% -$0.65 $28.6M -
What do Analysts Say About IMCC or PLUR?
IM Cannabis Corp. has a consensus price target of --, signalling upside risk potential of 304.95%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 273.83%. Given that IM Cannabis Corp. has higher upside potential than Pluri, Inc., analysts believe IM Cannabis Corp. is more attractive than Pluri, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IMCCIM Cannabis Corp.0 0 0 PLURPluri, Inc.1 0 0 -
Is IMCC or PLUR More Risky?
IM Cannabis Corp. has a beta of 2.180, which suggesting that the stock is 117.961% more volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.575, suggesting its less volatile than the S&P 500 by 42.476%.
-
Which is a Better Dividend Stock IMCC or PLUR?
IM Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IM Cannabis Corp. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMCC or PLUR?
IM Cannabis Corp. quarterly revenues are $10.1M, which are larger than Pluri, Inc. quarterly revenues of $316K. IM Cannabis Corp.'s net income of -$2.8M is higher than Pluri, Inc.'s net income of -$6.1M. Notably, IM Cannabis Corp.'s price-to-earnings ratio is -- while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IM Cannabis Corp. is 0.14x versus 17.55x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMCCIM Cannabis Corp.0.14x -- $10.1M -$2.8M PLURPluri, Inc.17.55x -- $316K -$6.1M
-
Which has Higher Returns IMCC or RAPH?
Raphael Pharmaceutical, Inc. has a net margin of -27.9% compared to IM Cannabis Corp.'s net margin of --. IM Cannabis Corp.'s return on equity of -135.96% beat Raphael Pharmaceutical, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IMCCIM Cannabis Corp.19.72% -$0.55 $15.7M RAPHRaphael Pharmaceutical, Inc.-- -$0.01 -$1.2M -
What do Analysts Say About IMCC or RAPH?
IM Cannabis Corp. has a consensus price target of --, signalling upside risk potential of 304.95%. On the other hand Raphael Pharmaceutical, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that IM Cannabis Corp. has higher upside potential than Raphael Pharmaceutical, Inc., analysts believe IM Cannabis Corp. is more attractive than Raphael Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IMCCIM Cannabis Corp.0 0 0 RAPHRaphael Pharmaceutical, Inc.0 0 0 -
Is IMCC or RAPH More Risky?
IM Cannabis Corp. has a beta of 2.180, which suggesting that the stock is 117.961% more volatile than S&P 500. In comparison Raphael Pharmaceutical, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IMCC or RAPH?
IM Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Raphael Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IM Cannabis Corp. pays -- of its earnings as a dividend. Raphael Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMCC or RAPH?
IM Cannabis Corp. quarterly revenues are $10.1M, which are larger than Raphael Pharmaceutical, Inc. quarterly revenues of --. IM Cannabis Corp.'s net income of -$2.8M is lower than Raphael Pharmaceutical, Inc.'s net income of -$255K. Notably, IM Cannabis Corp.'s price-to-earnings ratio is -- while Raphael Pharmaceutical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IM Cannabis Corp. is 0.14x versus -- for Raphael Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMCCIM Cannabis Corp.0.14x -- $10.1M -$2.8M RAPHRaphael Pharmaceutical, Inc.-- -- -- -$255K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
